(RVTY) Revvity, Inc. Company Overview

What does Revvity do?

Revvity, Inc. is a health-science tools and diagnostics company listed on the New York Stock Exchange under RVTY. It supplies the instruments, reagents, assays, software, and laboratory services used to discover drugs, analyze cells and genes, manage scientific data, screen newborns and expectant mothers, and diagnose selected diseases. In plain English, Revvity sits behind the laboratory workflow: its customers are pharmaceutical and biotechnology companies, contract research organizations, hospitals, clinical laboratories, universities, and government institutions rather than mass-market consumers.

The company reports two nearly equal businesses—Life Sciences and Diagnostics—and markets in more than 160 countries. Its 2025 Form 10-K describes approximately 11,000 employees and a portfolio spanning translational multi-omics, imaging, biomarker identification, screening, informatics, and clinical testing. That breadth matters because Revvity can sell both consumable content and the instruments or software that make the content useful.

How does Revvity make money?

Revvity earns revenue through four linked economic engines. First, it sells laboratory instruments and automation platforms. Second, it sells reagents, antibodies, assay kits, microplates, and other consumables used repeatedly on those systems or in adjacent workflows. Third, it earns service revenue from maintenance, laboratory work, consulting, and support. Fourth, it sells scientific informatics and cloud-based software, including electronic laboratory notebooks and data-analysis platforms. Product revenue is generally recognized when control transfers; software, maintenance, consulting, and laboratory services are often recognized over the contract or service period.

Which segment contributes more revenue and profit?

Which products and geographies matter most?

The segment labels hide four economically distinct product families. Life Sciences Solutions generated $1.195 billion in FY2025 and includes research reagents, cell-analysis tools, imaging systems, automation, microplates, and genomic workflow products. Software contributed $236.4 million. Diagnostics consisted of $869.9 million of immunodiagnostics and $555.0 million of reproductive health revenue. This mix explains why the company can grow even when one laboratory end market slows: software, screening, antibodies, imaging, and immunodiagnostics respond to different budget cycles.

How global is the revenue base?

The Americas accounted for $1.256 billion, Europe for $825.0 million, and Asia for $775.1 million in FY2025. Europe carries more Diagnostics exposure than Life Sciences, while the Americas are more weighted toward Life Sciences. The geographic spread helps diversify demand, but it also creates foreign-exchange, tariff, data-privacy, reimbursement, and regulatory complexity.

How did PerkinElmer become Revvity?

Revvity’s current economics are the result of deliberate portfolio reconstruction rather than a simple corporate rename. The company inherited decades of scientific-instrument expertise, but the modern thesis is shaped by acquisitions that added high-value content and by divestitures that removed lower-growth applied testing and service operations.

1. 1937
   The predecessor company was founded as an advanced-technology enterprise. The long operating history created engineering, optics, detection, and laboratory-instrument capabilities that still support today’s workflow portfolio.
2. 1999
   The company adopted the PerkinElmer name, consolidating its identity around scientific and analytical technologies.
3. 2016–2019
   Acquisitions including EUROIMMUN and Tulip Diagnostics expanded immunodiagnostics and emerging-market clinical capabilities, increasing exposure to regulated diagnostic assays.
4. 2021
   The company completed the $5.25 billion BioLegend acquisition, adding antibodies and reagents in cytometry, proteogenomics, cell separation, and bioprocessing. This materially increased recurring content and also created substantial goodwill and debt.
5. 2022–2023
   Management agreed to sell Applied, Food, and Enterprise Services for $2.45 billion and completed the divestiture in March 2023. The transaction turned the remaining company into a focused Life Sciences and Diagnostics platform.
6. May 2023
   The company launched the Revvity brand and RVTY ticker, separating its identity from the divested PerkinElmer-branded businesses.
7. 2025–2026
   Management continued portfolio optimization, launched a new $1.0 billion repurchase authorization, made targeted acquisitions, and announced its intention to divest China Immunodiagnostics, which represented about 6% of FY2025 revenue.

What gives Revvity a competitive advantage?

Revvity’s moat is not one patent or one blockbuster product. The company’s 10-K explicitly says no single patent is material to the whole business. Its defensibility instead comes from a portfolio of proprietary reagents, assay chemistry, installed instruments, scientific software, regulated diagnostic workflows, manufacturing know-how, and customer trust. A laboratory that validates an assay, trains staff on an instrument, integrates software, and embeds data into regulated processes faces real switching costs even when an alternative product is available.

How strong are the moat components?

Who are the main competitors?

Revvity does not publish one simple competitor list because each workflow has a different rival set. Broad life-science platforms such as Thermo Fisher Scientific and Danaher compete across instruments, consumables, and laboratory workflows. Bio-Rad and Agilent overlap in selected instruments, reagents, and analytical tools. Illumina competes in genomic workflows, while Roche, Abbott, Siemens Healthineers, bioMérieux, and specialized diagnostic companies overlap in selected clinical categories. This is a practical overlap map, not a company-disclosed league table.

What does Revvity’s latest quarter show?

For the quarter ended April 5, 2026, revenue rose 7.0% to $711.1 million, while organic growth was 3.0%. Foreign exchange added roughly three percentage points and acquisitions added about one point; the quarter also included an extra fiscal week. The result therefore shows improving demand, but the reported growth rate should not be treated as a pure volume signal.

What changed beneath the headline?

Life Sciences revenue increased 6% to $361.8 million, helped by $13.5 million of growth in Life Sciences Solutions and $7.9 million in Software. Diagnostics revenue rose 8% to $349.3 million, including $20.6 million of growth in Reproductive Health and $4.3 million in Immunodiagnostics. Yet profitability did not rise at the same pace: gross margin fell 200 basis points to 54.5%, and adjusted operating margin fell from 25.6% to 23.6%. Product mix, foreign exchange, tariffs, strategic software and product-development investment, and the extra week all pressured margins.

The Q1 FY2026 earnings release also introduced pro forma guidance excluding China Immunodiagnostics: FY2026 revenue of $2.81–$2.84 billion, pro forma organic growth of 3%–4%, and pro forma adjusted EPS of $5.20–$5.30. The accompanying Form 10-Q is the more useful source for GAAP cash flow, debt, tariff costs, and restructuring detail.

How strong are profitability, cash flow, and the balance sheet?

FY2025 revenue increased 3.7% to $2.856 billion, but the quality of earnings requires reconciliation. GAAP operating income was $356.6 million, or 12.5% of revenue, while adjusted operating income was $773 million, or 27.1%. The difference primarily reflects $335.6 million of intangible amortization plus restructuring, transformation, litigation, acquisition, and other adjustments. Analysts should therefore examine both views: adjusted results better approximate current segment operations, while GAAP results capture the economic consequences of acquisition-heavy strategy.

Does cash conversion support reinvestment?

The cash-generation profile is solid, but FY2025 repurchases exceeded internally generated cash after capital expenditure. That was possible because Revvity entered the year with substantial cash and had access to debt markets. At April 5, 2026, cash was $860.3 million, total debt was approximately $3.208 billion, and net debt was about $2.348 billion. The company also disclosed $1.5 billion of revolving-credit capacity.

Who owns Revvity stock, and how is it governed?

Revvity has a conventional single-class public-company structure rather than founder-controlled super-voting shares. The investor base is highly institutional. According to the 2026 proxy statement, four disclosed holders each owned more than 5% and together represented approximately 48.3% of the outstanding shares using the Schedule 13G information cited in the proxy. This concentration does not give one holder control, but it makes capital allocation, executive incentives, and governance responsiveness especially important.

What do governance and incentives signal?

The incentive design is analytically useful because it reveals management’s operating priorities. For 2025, the short-term plan weighted organic revenue growth and adjusted EPS at 40% each and free-cash-flow conversion at 20%. The long-term plan emphasized organic growth, free-cash-flow conversion, adjusted operating margin expansion, and relative total shareholder return. These metrics align with Revvity’s central challenge: convert portfolio quality into durable growth and cash without sacrificing margin.

Where can Revvity grow?

The opportunity set is broader than one product cycle. Biopharma customers need higher-throughput screening, better cell and gene analysis, multi-omics tools, and software that connects experimental data. Clinical laboratories need scalable newborn, prenatal, autoimmune, infectious-disease, and specialty testing. Revvity can grow by launching proprietary content, placing instruments, cross-selling software and services into the installed base, and acquiring niche technologies that fit existing workflows.

Which growth drivers are most decision-useful?

What risks could weaken Revvity’s outlook?

The most important risks are operationally connected. A slowdown in pharmaceutical research can reduce instrument placements and reagent consumption. Lower volumes can hurt margins because manufacturing and R&D contain fixed costs. Acquisitions can then become harder to justify, increasing the chance that goodwill or acquired technology must be impaired. At the same time, global manufacturing exposes the company to tariffs, currency movements, supply constraints, and country-specific regulation.

Which filing risks have visible financial consequences?

The central risk is therefore not one catastrophic event; it is a chain reaction in which softer demand, unfavorable mix, tariffs, and fixed costs compress margins while debt and acquisition-related assets reduce room for error. The company’s filing also notes that its Life Sciences Solutions goodwill reporting unit exceeded carrying value by more than 10% but less than 20% in the 2025 impairment test, making growth assumptions particularly important.

Why does Revvity matter for valuation?

A DCF for Revvity should not begin with reported revenue growth alone. The model must separate organic growth from foreign exchange, acquisitions, divestitures, and fiscal-calendar effects. It should also distinguish GAAP operating margin from adjusted segment economics, explicitly forecast amortization and restructuring rather than hiding them, and connect reinvestment to future organic growth. Because the portfolio is nearly half Life Sciences and half Diagnostics, a single uniform growth rate can obscure materially different end-market cycles and margins.

Which KPIs best explain the business?

What should researchers monitor next?